Bitolterol compared to isoproterenol in advanced chronic obstructive pulmonary disease.
Twenty-eight patients with advanced emphysema and/or chronic bronchitis and severe airflow obstruction were randomly assigned to receive either bitolterol or isoproterenol aerosol delivered by a metered dose device which was administered three times daily. Randomization resulted in similar patients with like degrees of airflow obstruction and responsiveness to a test dose of inhaled bronchodilator. Significantly greater improvement in airflow was achieved by administration of bitolterol compared to isoproterenol. Pharmacologic responses continued after 90 days of daily dosing. Both drugs were well tolerated and side effects included mild degrees of tachycardia for both drugs. Two patients assigned to isoproterenol stopped therapy during the study due to side effects. This study indicates that bitolterol is more effective than isoproterenol in degree and duration of bronchodilatation in patients with advanced chronic obstructive pulmonary disease.
D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007545:Isoproterenol / Q000627:therapeutic use*; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D008297:Male; D008448:Maximal Expiratory Flow Rate; D008450:Maximal Midexpiratory Flow Rate; D008875:Middle Aged; D011674:Pulse / Q000187:drug effects; D014797:Vital Capacity / Q000187:drug effects
D004983:Ethanolamines; C011685:bitolterol; D007545:Isoproterenol